Shire is going to split itself into two, with one arm focused on rare diseases and the other on neuroscience, with separate reporting to begin from the first quarter of 2018 and a decision on a possible spin-off later this year. Announcing the changes at a healthcare conference in New York, chief executive Flemming Ornskov said the neuroscience unit, which makes drugs to control attention deficit hyperactivity disorder (ADHD), was not ready for a spin-out of the right now, with the split setting ...Den vollständigen Artikel lesen ...